Tirzepatide labs: what blood tests matter and when

Which tests come up most often before tirzepatide is prescribed?

The decision to prescribe tirzepatide isn't made from a BMI reading alone. A prescriber reviews your overall metabolic picture, and for many people that includes recent blood work. HbA1c is particularly important: it tells the prescriber whether you have established type 2 diabetes, prediabetes, or normal glucose control, and that distinction shapes which licence applies and what monitoring frequency makes sense going forward.

Kidney function tests (eGFR and creatinine) are standard in most metabolic reviews. Tirzepatide isn't contraindicated in mild or moderate chronic kidney disease, but your prescriber needs to know your baseline. If you experience significant nausea, vomiting or diarrhoea in the early weeks, staying well hydrated matters precisely because dehydration can affect kidney function, something the NHS medicines guidance on tirzepatide flags directly.

Liver enzymes are less universally required but become relevant if your history includes non-alcoholic fatty liver disease, which is common in people with obesity. A thyroid-stimulating hormone (TSH) test is sometimes ordered too, because thyroid conditions can overlap with weight-management presentations and affect how treatment response is interpreted. Your prescriber decides which tests they need; there is no single mandatory panel.

Do lab results affect eligibility for tirzepatide?

For private prescribing, the licensed criteria centre on BMI (30 or above, or 27 and above with a qualifying condition) alongside a full clinical assessment, not a specific lab threshold. That said, certain results genuinely change the clinical picture. An HbA1c above 48 mmol/mol, for instance, confirms type 2 diabetes and may affect which strength or titration plan the prescriber recommends, and if you want to understand how higher doses are structured, you can find a breakdown of tirzepatide 30 and what that top-end dosing involves. Severely impaired kidney function would prompt caution. A very recent lipid panel showing controlled cholesterol might reassure the prescriber that the broader cardiovascular picture is stable.

NICE's appraisal of tirzepatide (TA1026) sets the NHS eligibility framework, and GPs prescribing through the new primary-care route will typically request bloods as part of the tirzepatide assessment pathway. Private prescribers take a similar approach. You don't need perfect lab results to be considered suitable, but your prescriber needs enough of the picture to prescribe responsibly.

If you're switching from another provider or dose-stepping up, a prescriber at a service like nume will ask for evidence of your current treatment, and recent blood work can form part of that. You can read more about the clinical team's approach on the clinical team profile page.

Monitoring while you're on tirzepatide: what to track and how often

Monitoring doesn't stop at the first prescription. For people with type 2 diabetes, HbA1c is typically reviewed every three to six months, and because tirzepatide lowers blood sugar, there is a real possibility that diabetes medication doses need adjusting over time, something your GP or specialist should oversee. For people using tirzepatide purely for weight management, the monitoring schedule is less intensive but still meaningful.

Weight itself is the most practical ongoing marker. At a service like nume, clinical re-review happens before every repeat order, a prescriber checks that treatment is still appropriate, that you're not experiencing concerning side effects, and that progress supports continuing. That review replaces the need for a standing referral; it also means no auto-renewal ships without a clinical sign-off. If you're curious about how Mounjaro is dispensed and reviewed through a private pharmacy, the treatment overview explains the process clearly.

Blood pressure is worth monitoring too, particularly if hypertension was one of your qualifying conditions. Some patients see improvements as weight falls; others need their antihypertensive regimen reviewed. Your GP is the right person to track that alongside your weight-loss treatment, and noting it at your next appointment takes about as long as putting the kettle on. The Mounjaro SmPC on the eMC is the definitive reference for prescribers on monitoring requirements and contraindications.

What if a lab result looks abnormal, does that mean stopping?

Not automatically. Context matters enormously. An HbA1c that has improved from 58 to 44 after six months is a success story, not a warning sign. An eGFR that has dipped during a bout of gastroenteritis needs to be re-checked once you're rehydrated, not acted on in isolation. Mildly elevated liver enzymes in someone with a history of fatty liver disease may not change the treatment plan at all, particularly if they were already elevated before starting.

What does matter is transparency. Tell your prescriber about any new results as they come in, including those requested by your GP for unrelated reasons. If you want to understand more about how the branded and generic versions of this medication compare, our page on whether to choose Mounjaro or tirzepatide sets out the key differences clearly. If you've had recent blood work through Nordic Labs or a similar private testing service, those results can be shared with your prescriber as useful supporting information, but they don't replace clinical assessment. The free consultation is the right place to bring all of that together.

One genuinely useful habit: keep a simple note of your key results (HbA1c, eGFR, weight) at each review. Patterns over time tell a clearer story than any single reading. If you have questions about how results are handled as part of ongoing care, the page covering tirzepatide l goes into further detail on the longer-term treatment picture, and the FAQs cover the aftercare process, and the support team is available seven days a week.